Shared insight from a panel of key opinion leaders on the evolving treatment landscape of myeloproliferative neoplasms and improvements in care.
December 22nd 2022
Expert perspectives on the respective treatment landscapes of essential thrombocytopenia (ET) and polycythemia vera (PV) following the ASH 2022 Annual Meeting.
Shared insight on how a patient’s symptom burden can impact management strategies within essential thrombocytopenia and polycythemia vera.
January 5th 2023
Switching their focus to myelofibrosis management, expert panelists reflect on clinical data behind momelotinib, a novel JAK2 inhibitor.
Key opinion leaders on myeloproliferative neoplasms review clinical data behind pacritinib therapy in the setting of myelofibrosis.
January 12th 2023
A brief review of the biology of myelofibrosis, the potential for disease modification, and subsequent implications for treatment.
Closing out their discussion on the management of myelofibrosis, panelists highlight updated data with fedratinib and ruxolitinib, respectively.
January 19th 2023
Expert panelists consider the ongoing role of transplant for patients with myelofibrosis and discuss when it is more appropriate to explore systemic therapy options.
Key opinion leaders on myeloproliferative neoplasms review the potential of CALR as a therapeutic target following data from the ASH 2022 Annual Meeting.
January 26th 2023
A broad and comprehensive review of novel targeted agents under investigation in the setting of myeloproliferative neoplasm management.
Following their overview on novel treatment modalities in myeloproliferative neoplasms, expert panelists consider how best to sequence and manage novel therapies in practice.
February 2nd 2023
Closing out their discussion on myeloproliferative neoplasms, key opinion leaders share excitement for future evolutions in the treatment paradigm.